(Q44530802)

English

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

scientific article published in August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 December 2017

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results (English)

1 reference

Europe PubMed Central

3 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Nabholtz JM

1

1 reference

Europe PubMed Central

3 December 2017

Bonneterre J

2

1 reference

Europe PubMed Central

3 December 2017

Buzdar A

3

1 reference

Europe PubMed Central

3 December 2017

Robertson JF

4

1 reference

Europe PubMed Central

3 December 2017

Thürlimann B

5

1 reference

Europe PubMed Central

3 December 2017

publication date

1 August 2003

1 reference

Europe PubMed Central

3 December 2017

European Journal of Cancer

1 reference

Europe PubMed Central

3 December 2017

39

1 reference

Europe PubMed Central

3 December 2017

12

1 reference

Europe PubMed Central

3 December 2017

1684-1689

1 reference

Europe PubMed Central

3 December 2017

Tumor characteristics and clinical outcome of elderly women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900326-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900326-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900326-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900326-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900326-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900326-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900326-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(03)00326-5

1 reference

Europe PubMed Central

3 December 2017

1 reference

Europe PubMed Central

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44530802&oldid=2027002555"